ArticleJAMA2004

Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis".

Joseph D PiorkowskiPubMed ↗Publisher ↗

No numbers read from the abstract.